Contact | Print version | PDF version | Send article | RSS feed

Physiomics Announces License Agreement with Eli Lilly

07 Apr 2009 - Physiomics announced that it has signed a license agreement with Eli Lilly and Company. Under the terms of the agreement, Physiomics will license to Lilly a customised version of its "ModelPlayer” for in silico simulations of unspecified anticancer drugs and Lilly will have the option to purchase additional licenses.
 
‘We are delighted with the continued interest shown by Lilly in Physiomics’ technology. We hope that the capability for Lilly scientists to directly use Physiomics’ models will strengthen the quality of the interactions within our ongoing research collaborations. This is also an important commercial and technical milestone for Physiomics as this is the first time that we have out-licensed our technology.’